Cargando...
Treatment of Alzheimer’s Disease and Blood–Brain Barrier Drug Delivery
Despite the enormity of the societal and health burdens caused by Alzheimer’s disease (AD), there have been no FDA approvals for new therapeutics for AD since 2003. This profound lack of progress in treatment of AD is due to dual problems, both related to the blood–brain barrier (BBB). First, 98% of...
Gardado en:
| Publicado en: | Pharmaceuticals (Basel) |
|---|---|
| Autor Principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
MDPI
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7697739/ https://ncbi.nlm.nih.gov/pubmed/33207605 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph13110394 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|